Core Viewpoint - The article discusses the innovative drug "Zelime" (Bimekizumab), which is the first approved topical treatment for atopic dermatitis in children over 2 years old and adults, highlighting its unique mechanism of action and safety profile. Group 1: Drug Information - Zelime is a new topical ointment for treating eczema (atopic dermatitis) [2] - It is a domestically developed drug with international quality, approved simultaneously in China, the US, and Japan [3] - Zelime is not a steroid; it functions as an AhR modulator with a novel mechanism [4][5] Group 2: Efficacy and Usage - Zelime works by improving skin inflammation and barrier damage through antibacterial and antioxidant effects [6] - Patients often report quick relief from itching, with significant improvement within hours or by the second day of use [8] - The efficacy rate for children after 8 weeks of treatment is over 70%, with a higher rate of 83.9% for children aged 7-11 [9][10] Group 3: Safety and Side Effects - Zelime is safe for use, primarily acting locally on the skin and not easily absorbed into the bloodstream [15] - Common side effects may include mild, temporary reactions like folliculitis, which usually resolve on their own [15][18] - Long-term clinical trials indicate that Zelime can be used safely for extended periods without dependency or skin thinning [16][17] Group 4: Application Guidelines - The recommended application is twice daily, applying a thin layer to affected areas [20] - It is suitable for children aged 2 and older, with no specific precautions for elderly patients [22][26] - Zelime should be stored at room temperature, not exceeding 30°C, and does not require refrigeration [29][40] Group 5: Availability and Prescription - Zelime is a prescription medication and can be purchased online and in select pharmacies [28][43] - Currently, it is not covered by health insurance as it is a new drug [42]